ClinicalTrials.gg
CompletedNCT01888874DARWIN1Updated Nov 17, 2020Results posted

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

A Phase 2 interventional study of GLPG0634 and Placebo in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 142 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
5th of 17
599 · median 287
Started
2013
with 1 other
Phase 2
6 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
6 of 17
Galapagos NV

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 2, and was the 3rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram [mg], 100 mg and 200 mg daily -, each evaluated as once daily [QD] and twice daily [BID] regimen) or matching placebo for 24 weeks.

•During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses and dose regiments of GLPG0634 administration on participants' disability, fatigue, and quality of life were evaluated.

Read the detailed description
  • Treatment duration was 24 weeks in total.
  • However, at Week 12, participants on placebo who did not achieve a 20% improvement in swollen joint count(SJC66) and tender joint count (TJC68) were re-randomized (automatically via interactive voice/web response [IXRS]) to treatment to receive GLPG0634 100 mg QD or 50 mg BID doses in a blinded fashion, participants on 50 mg QD who had not achieved a 20% improvement in SJC66 and TJC68 were assigned to 100 mg QD and participants on 25 mg BID. who did not achieve a 20% improvement in SJC66 and TJC68 were assigned to 50 mg BID. All continued the study until Week 24.
  • Participants in the other groups maintained their randomized treatment until Week 24.
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Methotrexate inadequate responders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,
  • have ≥6 swollen joints (from a 66 joint count) and ≥8 tender joints (from a 68 joint count) at Screening and at Baseline,
  • Screening serum c-reactive protein ≥0.7 x upper limit of laboratory normal range (),
  • have received MTX for ≥6 months and have been on a stable dose (15 to 25 mg/week) of MTX for at least 4 weeks prior to Screening and willing to continue on their current regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are allowed when there is documented evidence of intolerance or safety issues at higher doses.

Exclusion criteria

Exclusion Criteria:

  • current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than MTX,
  • current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs administered in a single clinical study setting more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,
  • previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
599 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent \[%\] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.

    Drug: Placebo

  • Experimental
    GLPG0634 50 mg QD

    Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 100 mg QD

    Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 200 mg QD

    Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 25 mg BID

    Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 50 mg BID

    Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.

    Drug: GLPG0634

  • Experimental
    GLPG0634 100 mg BID

    Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.

    Drug: GLPG0634

Interventions

  • GLPG0634 capsules.

  • DrugPlacebo

    Placebo capsules.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12

    The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving an ACR20 Response at Week 24

    ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

    Time frame: Week 24

  2. Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24

    ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  3. Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24

    ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  4. ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24

    The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used).

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  5. Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24

    DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used.

    Time frame: Weeks 1, 2, 4, 8, 12, and 24

  6. Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24

    A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used.

    Time frame: Weeks 2, 4, 8, 12, and 24

  7. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24

  8. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24

    The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, and 24

  9. Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24

    FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used.

    Time frame: Baseline and Weeks 4, 12, and 24

  10. Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24

    The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used.

    Time frame: Baseline and Weeks 4, 12, and 24

07

Results

Posted Nov 17, 2020

Participant flow

Participants were enrolled at study sites in Europe, South America, North America, Australia, and New Zealand. The first participant was screened on 17 July 2013. The last study visit occurred on 14 May 2015.

Period 1 (Baseline up to Week 12)
Participant flow — Period 1 (Baseline up to Week 12)
MilestonePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Started86828586868584
Completed83767880778083
Not completed3676951
Withdrew: Withdrawal by subject2234300
Withdrew: Other1011330
Withdrew: Physician decision0000001
Withdrew: Adverse event0231210
Withdrew: Adverse event and treatment failure0000100
Withdrew: Non-compliance with the study procedures0100000
Withdrew: Lost to follow-up0100010
Period 2 (Week 13 to Week 24)
Participant flow — Period 2 (Week 13 to Week 24)
MilestonePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Started5357112806011283
Completed5055104785710980
Not completed3282333
Withdrew: Withdrawal by subject1120100
Withdrew: Adverse event and treatment failure0000100
Withdrew: Non compliance with study medication0020010
Withdrew: Treatment failure0010000
Withdrew: Adverse event2032113
Withdrew: Lost to follow-up0100010

Outcome measures

PrimaryPercentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12

The American College of Rheumatology (ACR) response is a measurement of improvement in multiple disease assessment criteria. The ACR20 response is defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used (ie, to impute a missing response, the participant was assumed to be a non-responder).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 1244.256.163.568.6576078.6
Statistical analysis
  • Placebo vs GLPG0634 50 mg QD · Regression, Logistic · p = 0.1236 · Difference in percentage rates: 11.9 · 95% CI -3.1 to 26.9P-value has been corrected for multiplicity according to Hommel's closed-testing method.
  • Placebo vs GLPG0634 100 mg QD · Regression, Logistic · p = 0.0435 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 19.3 · 95% CI 4.7 to 34
  • Placebo vs GLPG0634 200 mg QD · Regression, Logistic · p = 0.0068 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 24.4 · 95% CI 10.1 to 38.8
  • Placebo vs GLPG0634 25 mg BID · Regression, Logistic · p = 0.1236 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 12.8 · 95% CI -2 to 27.6
  • Placebo vs GLPG0634 50 mg BID · Regression, Logistic · p = 0.1056 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 15.8 · 95% CI 1 to 30.6
  • Placebo vs GLPG0634 100 mg BID · Regression, Logistic · p = < 0.0001 (P-value has been corrected for multiplicity according to Hommel's closed-testing method.) · Difference in percentage rates: 34.4 · 95% CI 20.7 to 48.1
SecondaryPercentage of Participants Achieving an ACR20 Response at Week 24

ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR20 Response at Week 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Percentage of Participants Achieving an ACR20 Response at Week 2441.954.961.273.355.86079.8
SecondaryPercentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24

ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2. Patient's Global Assessment of Disease Activity VAS 3. Physician's Global Assessment of Disease Activity VAS 4. Total HAQ-DI score 5. CRP. Non-responder imputation was used.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Week 11.22.44.74.73.57.17.1
Week 25.87.32010.5711.821.4
Week 4713.432.917.415.118.834.5
Week 812.826.835.333.725.634.145.2
Week 1215.132.937.64327.934.154.8
Week 2416.335.447.15034.935.354.8
SecondaryPercentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24

ACR70 response: 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2. Patient's Global Assessment of Disease Activity VAS, 3. Physician's Global Assessment of Disease Activity VAS, 4. Total HAQ-DI score, and 5. CRP. Non-responder imputation was used.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Week 11.2001.21.22.44.8
Week 21.22.47.15.82.35.93.6
Week 43.57.314.14.75.89.410.7
Week 871123.518.69.314.127.4
Week 128.115.921.224.41418.831
Week 249.32232.929.120.923.539.3
SecondaryACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24

The ACR-N is the smallest percentage improvement in swollen and tender joints and the median of the remaining 5 core parameters, and is expected to be more sensitive to change than the ACR20, ACR50 or ACR70. It is a number varying between 0 and 100, with higher numbers indicating less severity of symptoms. Last observation carried forward (LOCF) algorithm was used (ie, to impute a missing value, the last preceding nonmissing value was used).

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · percentage of improvement
ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of improvementPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Week 19.27 ± 1.51910.31 ± 1.57814.69 ± 2.0414.25 ± 1.8229.01 ± 1.60311.36 ± 1.93917.63 ± 2.206
Week 213.85 ± 1.94916.36 ± 2.12525.2 ± 1.98622.61 ± 2.51715.2 ± 2.06320.01 ± 2.4727.77 ± 2.606
Week 416.93 ± 2.33221.08 ± 2.59831.32 ± 3.35427.45 ± 2.57323.17 ± 2.66826.37 ± 2.96135.69 ± 2.861
Week 821.6 ± 2.64430.16 ± 3.01538.24 ± 3.48437.88 ± 3.09731.2 ± 2.84533.4 ± 3.1545.36 ± 3.246
Week 1223.09 ± 2.91134.03 ± 3.33539.87 ± 3.44942.1 ± 3.27734.12 ± 3.14435.86 ± 3.2951.17 ± 3.379
Week 2422.06 ± 2.84637.13 ± 3.58250.86 ± 3.64550.4 ± 3.29138.56 ± 3.38440.5 ± 3.29958.69 ± 3.204
SecondaryPercentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24

DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None = Actual DAS28 (CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28 (CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28 (CRP) from baseline \> 1.2, or Actual DAS28 (CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline \> 0.6 to ≤ 1.2; Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline \> 1.2. LOCF algorithm was used.

Time frame:
Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Week 1: None73615842636440
Week 1: Moderate21383555343249
Week 1: Good61733511
Week 2: None58493931514420
Week 2: Moderate33454253434662
Week 2: Good96191561118
Week 4: None56442916373515
Week 4: Moderate34464065444261
Week 4: Good10103119192224
Week 8: None4434201524248
Week 8: Moderate43455249514946
Week 8: Good13212836242745
Week 12: None413318828157
Week 12: Moderate45444855445643
Week 12: Good14233437282850
Week 24: None4833121023145
Week 24: Moderate34353838374931
Week 24: Good19325151403664
SecondaryPercentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24

A participant's disease activity status can be defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and Patient Global Assessment of Disease Activity (cm) are all ≤ 1. Non-responder imputation was used.

Time frame:
Weeks 2, 4, 8, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24
percentage of participantsPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Week 2003.50001.2
Week 41.21.21.22.3002.4
Week 81.23.73.53.51.21.23.6
Week 123.53.73.55.84.74.79.5
Week 241.2118.211.65.83.519
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), Physician's Global Assessment of Disease Activity (in cm), and CRP (mg/dL). The SDAI was categorized as follows: • High disease activity: SDAI \> 26 • Moderate disease activity: 11 to 26 • Low disease activity: 3.3 to 11 • Remission: ≤ 3.3. LOCF algorithm was used. The SDAI total score ranges from 0 to approximately 86.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Baseline43.756 ± 1.271743.77 ± 1.349945.42 ± 1.390945.611 ± 1.336243.951 ± 1.322444.794 ± 1.404344.542 ± 1.3097
Change at Week 1-8.3 ± 1.25-8 ± 1.14-12.2 ± 1.45-12.8 ± 1.29-8.2 ± 1.17-10 ± 1.22-14.5 ± 1.31
Change at Week 2-11.4 ± 1.45-12.5 ± 1.46-18.6 ± 1.64-16.4 ± 1.35-13.4 ± 1.29-15.1 ± 1.43-20.3 ± 1.35
Change at Week 4-13.1 ± 1.47-16.3 ± 1.64-22.7 ± 1.78-22.2 ± 1.28-17.8 ± 1.44-19.3 ± 1.74-24.9 ± 1.54
Change at Week 8-16.3 ± 1.64-20.1 ± 1.86-24.6 ± 1.57-25.9 ± 1.57-22.2 ± 1.68-23.2 ± 1.8-29.2 ± 1.58
Change at Week 12-16.3 ± 1.84-21 ± 1.84-25.2 ± 1.69-27.2 ± 1.55-22.3 ± 1.71-24.5 ± 1.87-30.6 ± 1.57
Change at Week 24-15.8 ± 2-22.8 ± 2.07-30.1 ± 1.66-31 ± 1.66-24.9 ± 1.85-27.9 ± 2-34.4 ± 1.47
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24

The CDAI is the SDAI modified to exclude CRP and is the sum of the 4 outcome parameters: TJC28, SJC28, Patient Global Assessment of Disease Activity (in cm), and Physician's Global Assessment of Disease Activity (in cm). The CDAI was be categorized as follows: • High disease activity: \> 22 • Moderate disease activity: 10 to 22 • Mild disease activity: 2.8 to 10 • Remission: ≤ 2.8. LOCF algorithm was used. The CDAI total score ranges from 0 to approximately 76.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Baseline42.131 ± 1.23640.999 ± 1.210442.966 ± 1.301442.901 ± 1.284441.347 ± 1.244242.333 ± 1.318641.856 ± 1.2462
Change at Week 1-8.5 ± 1.23-7.2 ± 1.09-11.1 ± 1.38-11.1 ± 1.22-7.3 ± 1.14-9 ± 1.15-12.8 ± 1.27
Change at Week 2-11.6 ± 1.43-11.7 ± 1.39-17.3 ± 1.58-14.6 ± 1.29-12.4 ± 1.26-14 ± 1.38-18.4 ± 1.31
Change at Week 4-13.3 ± 1.42-15.2 ± 1.54-21.4 ± 1.71-20.4 ± 1.24-17.1 ± 1.35-18 ± 1.71-22.8 ± 1.51
Change at Week 8-16.4 ± 1.58-18.9 ± 1.78-23.4 ± 1.52-24.2 ± 1.15-21.1 ± 1.67-21.9 ± 1.75-27.1 ± 1.53
Change at Week 12-16.6 ± 1.84-19.7 ± 1.77-23.8 ± 1.66-25.5 ± 1.5-21.3 ± 1.65-23.2 ± 1.81-28.5 ± 1.49
Change at Week 24-16 ± 1.95-21.3 ± 1.97-28.6 ± 1.63-29.4 ± 1.5-23.8 ± 1.75-26.7 ± 1.9-32.4 ± 1.39
SecondaryChange From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24

FACIT-Fatigue scale is a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated that are scored reversely), the greater the fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating a better quality of life. LOCF algorithm was used.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Baseline26.2 ± 1.0926.2 ± 1.126.6 ± 1.0625.2 ± 1.2528.1 ± 1.1826.2 ± 1.0425.6 ± 1.25
Change at Week 44.9 ± 1.064.4 ± 1.119.1 ± 1.148.5 ± 1.234.5 ± 1.066.6 ± 0.889.9 ± 0.97
Change at Week 125.6 ± 1.067.6 ± 1.269.5 ± 1.2111.4 ± 1.376.9 ± 1.128.4 ± 1.0811.3 ± 1.25
Change at Week 246 ± 1.047.9 ± 1.2111.1 ± 1.211.6 ± 1.337.7 ± 1.179 ± 1.0412.8 ± 1.36
SecondaryChange From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24

The SF-36 is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Two summary scale scores were computed based on weighted combinations of the 8 domain scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). LOCF algorithm was used.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24
units on a scalePlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
PCS at Baseline32.999 ± 0.712132.691 ± 0.747431.636 ± 0.792631.625 ± 0.635531.364 ± 0.685831.332 ± 0.72632.249 ± 0.7844
PCS Change at Week 43 ± 0.654.1 ± 0.886.1 ± 0.986.4 ± 0.875 ± 0.694.2 ± 0.87.2 ± 0.77
PCS Change at Week 123.2 ± 0.746.7 ± 18.4 ± 0.938.9 ± 0.97.5 ± 0.927.1 ± 0.9610.5 ± 0.98
PCS Change at Week 242.8 ± 0.757.3 ± 1.029.9 ± 1.099.7 ± 0.997.8 ± 0.857.9 ± 0.9111.6 ± 1.1
MCS at Baseline42.849 ± 1.086142.199 ± 1.258143.953 ± 1.111841.362 ± 1.142745.527 ± 1.28844.748 ± 1.22842.059 ± 1.2898
MCS at Week 43 ± 0.923.4 ± 0.914.9 ± 0.855.4 ± 0.982.4 ± 0.782.7 ± 0.845.6 ± 0.92
MCS at Week 124.3 ± 1.054.4 ± 1.115.1 ± 0.968.1 ± 1.173.5 ± 0.973.1 ± 1.026.2 ± 0.98
MCS at Week 244.7 ± 0.964.3 ± 1.046.7 ± 0.917.2 ± 1.123.8 ± 0.963.5 ± 1.017.1 ± 1.21

Adverse events

Collected over Baseline through end of study drug treatment (average exposure: 160.7 days) plus 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/86 (0%)4/86 (4.7%)11/86 (12.8%)
GLPG0634 50 mg QD0/82 (0%)0/82 (0%)23/82 (28%)
GLPG0634 100 mg QD0/119 (0%)4/119 (3.4%)13/119 (10.9%)
GLPG0634 200 mg QD0/86 (0%)2/86 (2.3%)21/86 (24.4%)
GLPG0634 25 mg BID0/86 (0%)2/86 (2.3%)23/86 (26.7%)
GLPG0634 50 mg BID0/117 (0%)0/117 (0%)22/117 (18.8%)
GLPG0634 100 mg BID1/84 (1.2%)3/84 (3.6%)15/84 (17.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
Lower limb fractureInjury, poisoning and procedural complications0/860/820/1190/860/860/1171/84
PancytopeniaBlood and lymphatic system disorders0/860/820/1190/860/860/1171/84
VertigoEar and labyrinth disorders0/860/820/1190/860/860/1171/84
PneumoniaInfections and infestations0/860/821/1190/860/860/1171/84
Intervertebral discitisInfections and infestations0/860/820/1190/860/860/1171/84
Septic shockInfections and infestations0/860/820/1190/860/860/1171/84
Pericardial effusionCardiac disorders1/860/820/1190/860/860/1170/84
HyperventilationRespiratory, thoracic and mediastinal disorders1/860/820/1190/860/860/1170/84
Ischaemic cerebral infarctionNervous system disorders0/860/820/1190/861/860/1170/84
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/860/820/1191/860/860/1170/84
Most frequent other events
Most frequent other events
EventPlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BID
NasopharyngitisInfections and infestations4/868/823/1193/864/862/1174/84
NauseaGastrointestinal disorders3/867/820/1193/863/863/1171/84
HeadacheNervous system disorders4/861/821/1196/866/863/1172/84
HypercholesterolaemiaMetabolism and nutrition disorders0/862/820/1195/862/861/1174/84
GastroenteritisInfections and infestations0/861/821/1192/865/862/1171/84
VomitingGastrointestinal disorders1/860/820/1190/860/866/1172/84
Upper respiratory tract infectionInfections and infestations1/862/822/1194/864/866/1172/84
HypertensionVascular disorders2/863/826/1194/863/864/1171/84

Baseline characteristics

Safety population included all participants who were randomized and received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Mean52 (18 to 84)52.8 (20 to 77)52.3 (20 to 79)54.8 (19 to 75)52.4 (24 to 79)55.4 (21 to 78)53.9 (22 to 76)53.4 (18 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Female70696574686570481
Male16132012182014113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Hispanic or Latino37373333373038245
Not Hispanic or Latino49455253495546349
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
American Indian or Alaska Native00000000
Asian00100102
Native Hawaiian or Other Pacific Islander00000000
Black or African American10010013
White59616267636566443
More than one race26212218231917146
Unknown or Not Reported00000000
Rheumatoid Arthritis (RA) duration
Rheumatoid Arthritis (RA) duration(years)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Mean8.21 (0.5 to 36.5)7.21 (0.6 to 21.3)7.67 (0.6 to 32.6)8.51 (0.5 to 34.5)8.88 (0.5 to 30.1)7.79 (0.5 to 28.8)9.74 (0.5 to 43.2)8.29 (0.5 to 43.2)
C-reactive protein (CRP) at Baseline
C-reactive protein (CRP) at Baseline(milligram per liter (mg/L))PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Mean16.25 (1 to 84.5)27.71 (1 to 158.7)24.54 (1 to 140.7)27.1 (1 to 140.9)26.01 (1.2 to 157.3)24.6 (1 to 113.4)26.86 (1 to 129.4)24.70 (1 to 158.7)
Corrected tender joint count based on 68 joints (TJC68) at Baseline
Corrected tender joint count based on 68 joints (TJC68) at Baseline(joint count)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Mean24.984 (8 to 60)24.907 (8 to 64)25.319 (8 to 68)28.843 (8 to 68)25.427 (8 to 64)27.158 (8 to 66)25.946 (7 to 61)26.091 (7 to 68)
Corrected swollen joint count based on 66 joints (SJC66) at Baseline
Corrected swollen joint count based on 66 joints (SJC66) at Baseline(joint count)PlaceboGLPG0634 50 mg QDGLPG0634 100 mg QDGLPG0634 200 mg QDGLPG0634 25 mg BIDGLPG0634 50 mg BIDGLPG0634 100 mg BIDTotal
Mean16.13 (6 to 48)17.023 (6 to 66)16.31 (6 to 54)17.355 (6 to 58)15.663 (6 to 40)17.534 (6 to 62)16.356 (6 to 48)16.622 (6 to 66)
08

Study locations

142 sites
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama, United States
  • Artho Care, Arthritis Care & Research P.C.
    Gilbert, Arizona, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Phoenix, Arizona, United States
  • C.V. Mehta MD Medical Corporation
    Hemet, California, United States
  • Center for Innovative TherapyDivision of Rheumatology, UCSD
    La Jolla, California, United States
  • Desert Medical Advances
    Palm Desert, California, United States
  • Desert Valley Medical Center
    Victorville, California, United States
  • Infosphere Clinical Research, Inc.
    West Hills, California, United States
  • RASF Clinical Research Center
    Boca Raton, Florida, United States
  • Millennium Research
    Ormond Beach, Florida, United States
  • Lovelace Scientific Resources
    Venice, Florida, United States
  • Arthritis Center of North GA
    Gainesville, Georgia, United States
  • Idaho Arthritis Center
    Meridian, Idaho, United States
  • The Arthritis Center
    Springfield, Illinois, United States
  • Professional Research Network of Kansas
    Wichita, Kansas, United States
  • Arthritis Treatment Center
    Frederick, Maryland, United States
  • Klein and Associates MD
    Hagerstown, Maryland, United States
  • Private practice
    Lansing, Michigan, United States
  • Mayo Clinic
    Rochester, Minnesota, United States
  • Physicians East
    Greenville, North Carolina, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma, United States
  • Altoona Center Clinical Research
    Duncansville, Pennsylvania, United States
  • Austin Rheumatology Research PA
    Austin, Texas, United States
  • Arthritis Centers of Texas
    Dallas, Texas, United States
  • Pioneer Research Solutions Inc
    Houston, Texas, United States
  • Crossroads Clinical Research, LLC
    Victoria, Texas, United States
  • Seattle Rheumatology Associates, PLLC
    Seattle, Washington, United States
  • Mountain State Clinical Research
    Clarksburg, West Virginia, United States
  • Atencion Integral en Reumatologa
    Buenos Aires, Argentina
  • Rheumatology OMI
    Buenos Aires, Argentina
  • Instituto Reumatologico
    Cordoba, Argentina
  • Instituto Medico CER
    Quilmes, Argentina
  • Instituto de Asistencia Reumatologia Integral
    San Fernando, Argentina
  • Centro Médico Privado de Reumatología
    Tucuman, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, Australia
  • Monash Medical Centre
    Clayton, Australia
  • Repatriation General Hospital
    Daw Park, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • Medical University/ AKH Vienna/ Dep.of Rheumatology 6J
    Wien, Austria
  • Cliniques Universitaires St-Luc
    Brussels, Belgium
  • Hospital Brugmann
    Brussels, Belgium
  • Rheuma Instituut
    Hasselt, Belgium
  • AZ Groeninge
    Kortrijk, Belgium
  • UZ Leuven
    Leuven, Belgium
  • CHU de Liège
    Liege, Belgium
  • "Multiprofile Hospital for Active Treatment - Kaspela" LTD
    Plovdiv, Bulgaria
  • MHAT Ruse AD
    Ruse, Bulgaria
  • Clinic of Rheumatology MHAT
    Sofia, Bulgaria
  • Diagnostic Consultative Center "Sveta Anna" LTD
    Sofia, Bulgaria
  • National Transport Hospital "Tsar Boris" III
    Sofia, Bulgaria
  • Rheumatology Clinic
    Sofia, Bulgaria
  • Hospital Regional "Guillermo Grant Benavente"
    Concepcion, Chile
  • Instituto Terapias Oncologicas Providencia
    Santiago, Chile
  • Prosalud
    Santiago, Chile
  • Someal SA
    Santiago, Chile
  • Centro de Investigacion Clínica del Sur Freire
    Temuco, Chile
  • Private Office
    Temuco, Chile
  • Centro Integral de Reumatologia de Caribe
    Barranquilla, Colombia
  • Fundación del caribe para la investigación medica Fundación BIOS
    Barranquilla, Colombia
  • Centro Integral de Reumatologia e Inmunologia SAS
    Bogota, Colombia
  • Cirei Sas
    Bogota, Colombia
  • Idearg S.A.S.
    Bogota, Colombia
  • Medicity S.A.S.
    Bucaramanga, Colombia
  • Clinica de Arthritis Temprana S.A.S.
    Cali, Colombia
  • Preventive Care SAS
    Cundinamarca, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, Colombia
  • Revmatologie S.R.O
    Brno, Czechia
  • Ambulance Revmatologie a Interniho Lekarstvi
    Kladno, Czechia
  • Revmatologicka ambulance
    Praha-Nusle, Czechia
  • Medical Plus, s.r.o.
    Uherske Hradiste, Czechia
  • PV-Medical
    Zlin, Czechia
  • Hopitaux universitaires de Strasbourg
    Strasbourg, France
  • Charite Mitte, Rheumatologie Neue Therapien
    Berlin, Germany
  • Schlossparkklinik - Akad. Lehrkrankenhaus Charite
    Berlin, Germany
  • Klinikum Goethe-Universität
    Frankfurt, Germany
  • Schwerpunktpraxis fuer Rheumatologie
    Hamburg, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, Germany
  • Centro Medico
    Guatemala City, Guatemala
  • Clinica de Especialidades Medicas
    Guatemala City, Guatemala
  • Clinica Medica Especializada en Reumatologia
    Guatemala City, Guatemala
  • Clinica Medica
    Guatemala City, Guatemala
  • Reuma S.A.
    Guatemala City, Guatemala
  • Reuma-Centro
    Guatemala, Guatemala
  • DRC
    Balatonfured, Hungary
  • Budai Irgalmasrendi Korhaz
    Budapest, Hungary
  • Qualiclinic Ltd
    Budapest, Hungary
  • Revita Clinic
    Budapest, Hungary
  • Markhot Ferenc Korhaz
    Eger, Hungary
  • Bekes Megyei Pandy Kalman Korhaz, Reumatologiai Osztaly
    Gyula, Hungary
  • Csolnoky Ferenc County Hospital
    Veszprem, Hungary
  • Carmel Medical Center
    Haifa, Israel
  • Rambam Medical Center
    Haifa, Israel
  • Sheba Medical Center
    Ramat Gan, Israel
  • M&M Centre Ltd.
    Adazi, Latvia
  • Meda D
    Daugavplis, Latvia
  • L. Atikes doktorats
    Liepaja, Latvia
  • "Bruninieku" polyclinic
    Riga, Latvia
  • Arija's Ancane's Family Doctor
    Riga, Latvia
  • Centro de Estudios de Investigacion Basica y Clinica, SC
    Guadalajara, Mexico
  • Arké Estudios Clínicos
    Mexico, Mexico

Showing the first 100 of 142 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7. PubMed 36205910 ↗
  • Tarrant JM, Galien R, Li W, Goyal L, Pan Y, Hawtin R, Zhang W, Van der Aa A, Taylor PC. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatol Ther. 2020 Mar;7(1):173-190. doi: 10.1007/s40744-019-00192-5. Epub 2020 Jan 7. PubMed 31912462 ↗
  • Westhovens R, Taylor PC, Alten R, Pavlova D, Enriquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19. PubMed 27993829 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Feb 2015, 19 months.

Results were first posted in Nov 2020, 5 years 8 months after primary completion. A results delay was requested in Apr 2016.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 19 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jun 28, 2013
StartActual
Jul 17, 2013
Primary completionActual
Feb 18, 2015
CompletionActual
May 14, 2015
Results delay requested
Apr 18, 2016
Results first posted
Nov 17, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01888874
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Jul 17, 2013
Primary completion
Feb 18, 2015
Completion
May 14, 2015
Results posted
Nov 17, 2020
Last update
Nov 17, 2020

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion